Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for cancer and infectious diseases.
Founded in 2007, Vaccibody is using its vaccine technology platform to generate best-in-class therapeutics in indications/diseases with a significant unmet medical need.
The Company is a leader in the rapidly evolving field of cancer vaccines and currently has two clinical-stage product candidates: a personalized cancer neoantigen vaccine and a vaccine against HPV16-related cervical cancer.
Vaccibody has 24 employees (end of 2019) located in Oslo, Norway, and collaborations with internationally renowned companies. Vaccibody’s shares are traded on the NOTC*.
Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Vaccibody’s vaccines specifically target Antigen Presenting Cells (APC), which are essential for inducing rapid, strong and specific immune responses and elicit efficacious clinical responses.
By intelligent design, Vaccibody’s vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need, such as cancer and infectious diseases.
The lead product candidates are VB10.NEO, a personalized therapeutic cancer neoantigen vaccine currently being evaluated in a Phase I/IIa clinical trial, and VB10.16, a therapeutic cancer vaccine against HPV16-related cancers currently being tested in a Phase II clinical trial.
Vaccibody’s vaccine platform offers advantages with respect to a number of important parameters, such as safety, immunogenicity and clinical efficacy, speed of development, and rapid manufacturing and scalability. This may grant Vaccibody a favorable position as a leader in the field of cancer vaccines and in the fight against infectious diseases.
VB10.NEO is the first personalized neoantigen cancer vaccine to demonstrate induction of strong cancerspecific immune responses which lead to favorable clinical responses. This has been demonstrated in several patients with locally advanced or metastatic disease in several indications.
While the Company solidifies the value of its vaccine platform in immuno-oncology in the clinic, it continues to build the platform for other disease areas, strengthening the team and the partnerships required to bring these innovative treatments to patients worldwide.
* NOTC is a marketplace for unlisted shares managed by NOTC AS, which is owned 100% by Oslo Børs ASA, the Oslo Stock Exchange.